Gapping up
In reaction to earnings/guidance:
- SMCI +16%, LYFT +13.1%, SGRY +12.1%, CRTO +12%, SPT +10.9% (also announces it will be bringing WhatsApp messaging into its product suite), CPRI +10%, CDLX +8.3%, PRG +8.1%, LIVN +7.6%, CWH +7.5%, TVTY +7.2%, ICPT +6%, TCS +5.4%, OSPN +5.3%, FRG +5.3%, SKY +4.9%, SHOO +4.8%, DNOW +4.5%, PACB +4.4%, PKI +3.9%, NYT +3.9%, FNF +3.6% (also increases dividend), VRTX +3.1%, TMUS +3.1%, CVE +2.8%, DVN +2.6% (also authorizes $1 bln share repurchase program; increases fixed-plus-variable dividend), DCPH +2.6%, SITE +2.5%, NVO +2.2%, VECO +2%, CHK +2%, SMG +2%, MDLZ +1.9%, GNW +1.8%, HALO +1.8%, PEAK +1.8%, KAR +1.7%, TSLX +1.7%, EGHT +1.7%, FMC +1.7%, BKH +1.7%, STE +1.4%, OMI +1.4%, AFG +1.3% (also declares $4/sh special dividend), PYR +1.3%, HRB +1.1%, RAMP +1.1%, ETR +1.1%, VIRT +1.1%, WEYS +1%, VSH +1%, UTHR +0.9%
Other news:
- BBBY +55.6% (to redefine business model; launches collaboration with Kroger; expects to complete $1 bln repurchase plan by end of FY21)
- RRD +40.3% (entered into a definitive merger agreement to be acquired by affiliates of Atlas Holdings in an all-cash transaction with a total enterprise value of ~$2.1 bln)
- IRTC +21.3% (Comments on Centers for Medicare and Medicaid Services 2022 Medicare Physician Fee Schedule Final Rule)
- FLGC +10% (announces definitive agreement to acquire Vessel Brand for aggregate consideration of $30 mln)
- MFGP +6.6% (to sell Digital Safe product line to Smarsh)
- AVRO +5.3% (FDA has granted Rare Pediatric Disease Designation to AVR-RD-05)
- DKS +3.3% (Dick's Sporting Goods and NIKE (NKE) have forged a transformative connected partnership designed to enhance the shopping experience for DICK'S and NIKE customers) FXLV +3% (announces commercial partnership with RCL)
- RTPY +2.6% (receives shareholder approval for combination with Aurora)
- BNTX +2.2% (vaccine recommended for kids 5-11 by CDC advisory panel)
- CUBE +1.7% (increases dividend)
- KR +1.3% (launches collaboration with BBBY)
- ABG +1.1% (prices offering of 3.3 mln shares of common stock at $182.00 per share)
- MOTN +1.1% (receives shareholder approval for combination with DocGo)
- ABCL +1% (highlights recent announcement of additional purchase by US govt of bamlanivimab with etesevimab from LLY)
Analyst comments:
- RACE +5% (upgraded to Buy from Hold at Societe Generale)
- TMUS +3.1% (upgraded to Strong Buy from Outperform at Raymond James)
- SHAK +2.7% (upgraded to Buy from Neutral at Northcoast)
- DD +1.6% (upgraded to Outperform from Neutral at Credit Suisse)
- INGR +1.6% (upgraded to Outperform from Neutral at Credit Suisse)
- ABEV +1.3% (upgraded to Neutral from Underperform at BofA Securities)
- WPP +1.3% (upgraded to Mkt Perform from Underperform at Bernstein)